CSL Research Acceleration Initiative

Applications close 24th February 2026

WHY COLLABORATE WITH CSL?

Funding
of up to $400,000 USD over 2 years

Access global capabilities and expertise
CSL scientific champion assigned to provide industry guidance and help you leverage our global capabilities

Publish with CSL
270+ publications with our collaborators since 2020

Accelerate
Translation of your research into new therapies

CSL is a leading global biotech company delivering innovative therapies to help people with life-threatening conditions live full lives.

The CSL **Research Acceleration Initiative** supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.

Successful applicants can receive up to **$400,000 USD in non-dilutive funding** over 2 years to advance their innovative programs.

Interested researchers are invited to:

- **Attend an information webinar (choose one of two sessions)**

  Thursday, 29 January 11:00AM EST – Click to join

  Thursday, 5 February 1:00PM EST – Click to join

- **Submit enquiries, expressions of interest and requests for application instructions to:**

  Name:

  Email:

- **Submit** a non-confidential, 500-word abstract via the CSL online application portal by **24th February 2026.**

The 2026 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area**. Please see over page for specific **Focus Areas**.

Therapeutic Areas



For additional information or enquiries, please reach out to: **RAI@CSL.COM.AU**

CSL Research Acceleration Initiative

Focus Areas

CSL is seeking applications that align with a CSL Therapeutic Area in the following Focus Areas

Transplant & Immunology

Novel first in class targets and drug concepts to treat immune-mediated diseases e.g.

- Strategies for targeting pathogenic T cell subsets
- Strategies for targeting disease-driving chemokine receptors
- Multi-specific approaches that enable multiple cell types/ pathways to be targeted to treat complex immune-mediated diseases
- Strategies for targeting stromal cells, senescence or inflammaging

Indication focus

- Chronic immune mediated rheumatologic and dermatologic diseases
- Rare neuro-immune disorders

Cardiovascular & Renal

Genetic rare renal diseases

Novel targets or therapeutic candidates for polycystic kidney disease autosomal dominant tubulointerstitial kidney disease and Alport syndrome

Autoimmune-mediated rare renal diseases

Novel targets or therapeutic candidates for autoimmune-mediated rare glomerular diseases and ANCA-associated vasculitis

Rare cardiovascular diseases

Novel targets or therapeutic candidates for inflammatory, autoimmune or genetic cardiomyopathies

Novel targets or therapeutic candidates for immune checkpoint inhibitor-induced myocarditis

Hematology

Acute hemorrhage control and Patient Blood Management (PBM)

- Pro-hemostatic therapies for anti-platelet agent-associated hemorrhage and intracerebral hemorrhage
- Treatments for targeting and preventing hyperfibrinolysis- and vascular malformations-associated bleeding

Transformative therapies for Hemophilia A

- Next generation non-AAV-based gene therapy
- Oral protein or nucleic acid-based treatments

Iron metabolism

- Novel treatments for iron deficiency and anemia
- Novel formulation approaches: oral & intramuscular iron supplementation
- Novel therapies to treat iron overload conditions
- Disease modifying therapies for myeloproliferative neoplasms including polycythemia vera , essential thrombocythemia, myelofibrosis and myelodysplastic syndrome

Acute thrombotic conditions

Novel therapies applicable to a broad spectrum of acute thrombotic diseases including microangiopathies (TMAs; pan-treatment)

Immunoglobulins

Patient Experience

- High concentration/low volume formulation technologies
- Improve ease of administration and decrease administration time for plasma-derived products
- Technologies that enable novel routes of administration for plasma-derived products

Novel Therapies for

- Primary and Secondary Immunodeficiency Disorders
- Alpha 1 Antitrypsin Deficiency

Optimization of human-derived Ig products

- Technologies that can optimize, supplement or replace human-derived products

Oral Delivery

Technologies enabling systemic oral delivery of biologics (e.g. antibodies and other large proteins)

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail **RAI@CSL.COM.AU** to discuss.